EVCARCO (OTC.BB:EVCA) is pioneering a new way to meet the demands of 21st century car buyers. EVCARCO is bringing to market eco-friendly vehicles with an emphasis on performance and affordability and the latest in developed technology. The board of EVCARCO is pleased to announce that, pursuant to a strong demand from the US Federal Government to meet environmental standards in relation to its Federal Military fleet, EVCARCO will be working with VENTA Inc. and several third party organizations to create Military grade AEV and Hybrid Diesel Electric units.

The move is part of an EVCARCO recent corporate shift aimed at increasing revenue through contracting and sourcing of units suitable for Government RFPs.

Scott O'Neal, Chief Operation Officer, stated, "We feel that working in conjunction with our corporate sales and commercial fleet division, the addition of a high revenue entity aimed at Military contracting is a significant move for EVCARCO and the corporate vision."

EVCARCO has been working on projects with the US Federal Government as announced in previous releases since first quarter of 2010; the trials have given the management of EVCARCO insight into the needs and requirements of the Federal Government and, with this knowledge, the corporation stands at a significant advantage in respect to sourcing specific AEV and Hybrid Units for the Military.

EVCARCO is the first automotive retail group dedicated to deploying a coast-to-coast network of eco-friendly dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric and alternative fuel vehicles. EVCARCO has developed a franchised dealer network allowing growth into most US States by 2012.

**************************************************************

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, reports that the United States Patent and Trademark Office issued AVI a patent granting key claims covering the use of phosphorodiamidate morpholino based oligomers (PMOs) as antibacterial agents. The patent, titled Antisense Antibacterial Method and Compound (No. 7,790,694), contains broad claims for the use of peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) to target the acyl carrier protein (AcpP), a gene considered essential for bacterial growth in both gram positive and gram negative bacteria.

"This patent represents an important addition to our intellectual property estate and further demonstrates the innovation and therapeutic potential of our unique RNA-based technology in the development of a new class of anti-infective agents," said J. David Boyle II, interim President and CEO of AVI BioPharma. "We believe that RNA-based therapeutics employing our advanced PMO chemistries can become an important new category of antibacterial agents. Instead of directly targeting proteins like most traditional antibiotics, our PMO-based compounds target key microbial RNAs to inhibit protein expression at the gene translation level. By leveraging our differentiated capabilities, AVI plans to rapidly advance novel antibacterial candidates in this increasingly important therapeutic area."

AcpP is an important component in the synthesis of fatty acids necessary for bacterial growth. Data from several in vitro and in vivo pre-clinical studies performed by AVI across multiple bacterial species demonstrate the potential breadth of AVI's antibacterial platform. AVI recently published data, accompanied by a related editorial commentary in the Journal of Infectious Diseases describing positive preclinical results from studies utilizing an AVI oligomer targeting AcpP against Burkholderia cepacia complex.

Preclinical studies performed by AVI and collaborators using its PMO-based compounds have provided encouraging data against gram positive and negative bacteria, which includes Burkholderia cepacia as well as E. coli, Bacillus anthracis, Mycobacterium and Salmonella. In in-vitro studies, AVI's compounds have demonstrated bactericidal activity against both antibiotic susceptible and resistant bacteria, and to date have not shown cross-resistance to other classes of antibiotics.

**************************************************************

Aviat Networks, Inc. (Nasdaq: AVNW), a leading wireless expert in advanced IP migration solutions, reports enhanced integrated Ethernet switching capabilities for its market leading Eclipse Packet Node microwave transmission platform to address the rapid growth of mobile broadband data traffic. The enhanced platform was successfully tested by the European Advanced Networking Testing Center (EANTC) in August at the industry's largest annual Carrier Ethernet interoperability test event and is being demonstrated this week at the Carrier Ethernet World Congress (CEWC) in Warsaw, Poland.

Mobile backhaul traffic continues to grow at a staggering pace globally driven by the proliferation of smart phones loaded with mobile data and video-intensive applications. As operators expand their backhaul networks to accommodate this surge, Ethernet-equipped microwave systems continue to serve a critical role. This was recently confirmed by Heavy Reading's 3Q10 Ethernet Backhaul Quarterly Market Tracker report, which projected 800 percent growth for Ethernet microwave deployed sites from 2010-2013. Having pioneered Hybrid or Dual Native Ethernet/TDM microwave solutions since the introduction of the Eclipse nodal wireless platform in 2004, Aviat Networks continues to evolve its portfolio to address the demands of emerging 4G/LTE networks requiring advanced Ethernet scalability, Quality of Service (QoS), traffic management, synchronization over packet networks and related features, which are designed to provide a smooth migration path to "all-IP" along with investment protection.

Advanced Ethernet switching capabilities for Eclipse Packet Node are being introduced on a new Gigabit Ethernet switching card—planned for introduction later this year—and will be offered alongside existing Eclipse Ethernet cards. It builds on Aviat Networks' field-proven experience and leadership in delivering versatile and scalable Hybrid and Packet microwave backhaul solutions and provides a seamless upgrade for customers who have already deployed Eclipse but need multi-Gigabit Ethernet transport with higher performance. In addition to synchronization over packet, the new card features advances in capacity, QoS, traffic management and Ethernet services, and supports new Ethernet protection options for high availability service assurance.

**************************************************************

Avid (NASDAQ: AVID) took a major step forward in the way it empowers aspiring and established musicians to achieve their creative vision -- however they define it. The company has introduced a set of tools -- including the new Pro Tools Mbox family, the M-Audio MobilePre, Pro Tools SE bundles and M-Audio Oxygen 88 keyboard controller -- for a range of musicians who are seeking to create, record and mix music at home or on the road.

Pro Tools Mbox family pricing begins at $399 for the Pro Tools Mbox Mini, $679 for Pro Tools Mbox and $899 for the Pro Tools Mbox Pro. Pro Tools Mbox and Pro Tools Mbox Mini are available worldwide this month. Pro Tools Mbox Pro will be available worldwide in Q4.

Pro Tools SE bundles begin at $99.99 for Avid Vocal Studio, $119.99 for Avid Recording Studio and $129.99 for Avid KeyStudio and will be available in the US this month.

MobilePre is currently available worldwide for $179.

Oxygen 88 is available worldwide for $749.95 beginning this month. All prices listed are USMSRP.

Avid creates the digital audio and video technology used to make the most listened to, most watched and most loved media in the world -- from the most prestigious and award-winning feature films, music recordings, television shows, live concert tours and news broadcasts, to music and movies made at home. Some of Avid's most influential and pioneering solutions include Media Composer, Pro Tools, Interplay, ISIS, VENUE, Oxygen 8, Sibelius, System 5, and Pinnacle Studio.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received fifteen thousand dollars in cash and thirty-five thousand dollars in EVCARCO, Inc. (EVCA.OB) restricted shares for 30 days of advertising.